It is important for oncology surgeon trainees to learn to recognize when a palliative surgical procedure for an advanced malignancy might be appropriate, be familiar with the conduct of these operations, and understand the nuances of postoperative care and management of complications in this unique patient population.
The FDA has expanded the approval of aprepitant injectable emulsion to include a 2-minute intravenous use for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
There have been efforts in recent years to improve patient adherence to oncology medications; now, oncologists may soon have 1 more tool in the form of digital pills.
The concept of chronic disease management in cancer has been and continues to be inadequately considered.
Gagandeep Brar, MD, reflects on patient interactions that she has encountered throughout her fellowship.
Jarushka Naidoo, MBBCh, discusses the toxicities associated with the use of immunotherapy in oncology, optimal methods of managing them, and the growing body of knowledge on why they occur.
The FDA has expanded the indication for the Orbis Paxman Hair Loss Cooling System to prevent chemotherapy-related alopecia in patients with solid tumors.
Both cognitive behavior therapy for insomnia (CBT-I) and acupuncture produced clinically meaningful improvements in insomnia severity scores for cancer survivors, but data from the randomized CHOICE clinical trial showed that CBT-I was more effective overall for reducing the severity of insomnia.
The FDA has approved the SYK inhibitor fostamatinib as a second-line treatment for patients with chronic immune thrombocytopenia following insufficient response to a previous therapy.
Hyman B Muss, MD, a 2017 Giants of Cancer Care® award winner is a pioneer in the treatment of older patients with cancer.